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1. Introduction 
Quinocarcin is a pentacyclic tetrahydroisoquinoline alkaloid, 
isolated by Takahashi and Tomita1 in 1983. Its intricate 
polycyclic architecture and potent broad-spectrum antitumor 
activity2,3 have attracted both synthetic and biological chemists, 
culminating in several efficient syntheses, reported by 
Fukuyama,4 Garner, Terashima, Myers, Zhu, and Stoltz.5 We 
recently reported the enantioselective total synthesis of (–)-
quinocarcin using Au(I)-catalyzed intramolecular 
hydroamination of alkynes (Scheme 1).6 In this synthesis, we had 
to overcome the challenging problem of cleaving the 
dihydrobenzofuran ring7,8 in 6, which was a key structural 
element for the 6-endo-dig over 5-exo-dig hydroamination. Based 
on the LiI-mediated ring-opening halogenation of benzofurans in 
the presence of SiCl4 and BF3·AcOH reported by Zewge et al.,7 
we attempted a ring-exchange strategy using neighboring group 
participation of the carbonyl oxygen of lactam 6 to afford an 
oxazolidinium intermediate 7. Exposure of lactam 6 to BF3·Et2O 
and SiCl4 in 1,2-dichloroethane (1,2-DCE) afforded a suspension, 
which possibly contained the expected oxazolidinium 
intermediate 7. Addition of H2O to the resulting suspension led to 
recovery of the starting material 6, but work-up with CsCl 
afforded the desired chlorinated phenol 8 in 92% yield. 
Based on these results, we thought that easier ring-opening of 
dihydrobenzofuran would be achieved by introduction of an 
appropriate nucleophilic functionality in the substrate. We 
embarked on an investigation to clarify the structural 
requirements which would accelerate the ring-opening reaction. 
Its synthetic application to the formal total synthesis of (–)-
































































































Scheme 1. Total synthesis of (–)-quinocarcin. 6 
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An unusual Lewis-acid-mediated ring-exchange reaction of dihydrobenzofurans is 
described. The fused tricyclic ring system is the key structural element for this reaction 
as it restricts C–N bond rotation and/or destabilizes the benzofuran ring. We achieved 
the formal total synthesis of (–)-quinocarcinamide using a combination of this reaction 








2. Results and discussion 
We tested our theory using the reaction of N-Boc- 
dihydroisoquinoline 9 (Scheme 2). Treatment of 9 with SiCl4 and 
BF3·Et2O in 1,2-DCE afforded oxazolidinone 10 in 84% yield. In 
this case, the reaction proceeded at room temperature and work-
up with CsCl (to suppress the reverse reaction) was not necessary. 
When the reaction was performed in the absence of BF3·Et2O, the 
starting material 9 was only recovered. This is in good 
accordance with the literature.7 This ring-exchange reaction is 
interesting and unusual because the normally stable 
dihydrobenzofuran ring can be selectively converted into the 
oxazolidinone by simultaneous C–O bond cleavage of the 
dihydrobenzofuran and C–O bond formation of the 
oxazolidinone ring. We thought that the possible requirements 
for the ring-exchange reaction would be: (1) restricted C–N bond 
rotation to give the appropriate arrangement of the carbonyl 
oxygen at the back of the furan C-O bond as shown in A, and (2) 
slightly distorted tricyclic ring systems in 6 and 9 to destabilize 
the benzofuran ring. Restriction of the C–N bond in 9 can be 
achieved by the tricyclic ring system and/or an aminomethyl 
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Scheme 2. Lewis-acid-mediated ring-exchange reaction of N-
Boc-dihydroisoquinoline 9. 
To clarify the structural requirements for the ring-exchange 
reaction, we investigated the reaction using N-Boc-3-
aminodihydrobenzofurans 11a–c (Table 1, entries 1–3). These 
substrates contain the minimum necessary functionalities for the 
reaction. Treatment of dihydrobenzofurans 11a–c with BF3·OEt2 
and SiCl4 in 1,2-DCE did not provide the oxazolidinones 12. 
Instead, amines 13a/b and 11a, formed by removal of the Boc 
group, were obtained in modest yields. Similarly, methyl 
carbamate 11d did not produce oxazolidinone 12b, but 
underwent elimination of methyl benzylcarbamate (entry 4). 
These observations show that (1) restricted C–N bond rotation 
and/or (2) a distorted tricyclic ring system are important for a 
successful ring-exchange reaction. 
We then investigated partial restriction of the C–N bond 
rotation by introduction of a substituent at the 4-position of the 
benzofuran ring. Treatment of 4-iododihydrobenzofurans 11e/f6 
with BF3·Et2O and SiCl4 only gave the corresponding amines 
13e/f, without promoting the ring-exchange reaction (entries 5 
and 6). In sharp contrast, tricyclic dihydroisoquinoline 11g (entry 
7), which was prepared by Sonogashira coupling of aryl iodide 
11e with phenylacetylene, followed by Au(I)-catalyzed 6-endo-
dig hydroamination of an alkyne, afforded the corresponding 
ring-exchange product 12g in 95% yield upon exposure to 
identical reaction conditions. When the tricyclic 
tetrahydroisoquinoline-type substrate 11h was used, the 
corresponding ring-exchange product 12h was obtained in 45% 
yield along with 18% yield of the amine 13h. These results 
showed that the appropriate fused ring structure, which would 
restrict the arrangement of the carbonyl oxygen and destabilize 
the benzofuran ring, is vital for this unusual ring-exchange 
reaction. Tricyclic dihydroisoquinoline substrate 11i, N-
methoxycarbonyl analogue of 11g, was also converted into the 
same phenol 12g albeit in lower yield (entry 9). Unfortunately, 
treatment of substrate 11j, with no substituent at the C-3 position 
of dihydroisoquinoline, led to a complex mixture of unidentified 
products (entry 10). On the other hand, when using substrate 11k, 
we obtained the resulting phenol 12k in 75% yield bearing a 
bromo substituent, which is useful for further elaborations. It is 
noteworthy that in this case SiBr4 was used in place of SiCl4 
because the reaction of the bromide 11k under the standard 
conditions caused halogen-exchange to form a considerable 
amount of the corresponding chloride (ca. 50% yield, judged by 
1H NMR and GC-MS, entry 11).  
Table 1 





















































































































aIsolated yields. No starting materials were recovered in all cases. bMethyl 
benzylcarbamate was formed in 59% yield. cSiBr4 was used in place of SiCl4. 
Next, we applied this ring-exchange reaction to the formal 
total synthesis of quinocarcinamide. Quinocarcinamide is formed 
by a Cannizzaro-type self-redox disproportionation of 
quinocarcin, which serves as its own reductant.9 As previously 
described,6 the optically active precursor 9 was prepared by 
Sonogashira coupling of the protected 4-iodo-2,3-
dihydrobenzofuran-3-amine (R)-11e with a propargylamine 
derivative, followed by Au(I)-catalyzed 6-endo-dig selective 
hydroamination of the corresponding alkyne 14 (Scheme 3). A 
Lewis-acid-mediated ring-exchange reaction of 9, shown in 
Scheme 2, subsequent methylation of the resulting phenol 10, 
and transesterification10 gave the optically active ethyl ester 15, 
whose spectral properties were identical to those reported for (±)-
15 by Flanagan and Williams in their total synthesis of (±)-
quinocarcinamide.11 This unusual Lewis-acid-mediated ring-
exchange reaction of dihydrobenzofuran therefore provides easy 























































Scheme 3. Application to the formal total synthesis of (–)-
quinocarcinamide. Reagents and conditions: a) methyl 2-
[methyl(propargyl)amino]acetate, Pd(OAc)2, n-Bu4NOAc, 
DMF, 80 °C; b) IPr–AuCl, AgNTf2, 1,2-DCE, 45 °C; c) 
Me2SO4, Cs2CO3, acetone, 0 °C; d) K2CO3, EtOH, 20 °C. 
IPr = 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene. 
 
3. Conclusions 
In summary, we investigated the Lewis-acid-mediated ring-
exchange reaction of dihydrobenzofurans. A tricyclic ring 
system for the restriction of the C–N bond rotation and/or 
destabilization of the benzofuran ring is the key structural 
element for the success of this ring-exchange reaction. A 
combination of this reaction with the Au(I)-catalyzed 6-endo-
dig hydroamination of an alkyne was used to achieve the 
formal total synthesis of (–)-quinocarcinamide. 
 
4. Experimental 
4.1 Lewis-acid-mediated ring-exchange reaction 
General procedure: synthesis of methyl (R)-2-{[(10-hydroxy-3-
oxo-3,10b-dihydro-1H-oxazol[4,3-a]isoquinolin-5-
yl)methyl](methyl)amino}acetate (10) (Scheme 2). SiCl4 (0.03 
mL, 0.27 mmol) and BF3·Et2O (0.004 mL, 0.03 mmol) were 
added to a stirred solution of 9 (20.4 mg, 0.05 mmol) in 1,2-DCE 
(2 mL) under argon at room temperature. After stirring for 4 h, 
Et3N (0.3 mL) and EtOH (2 mL) were added. An insoluble 
inorganic residue was filtered off and the filtrate was 
concentrated under reduced pressure. The residue was purified by 
column chromatography over silica gel with n-hexane–EtOAc 
(1:1) to give 10 as a white solid (14.5 mg, 84% yield): Rf = 0.24 
(n-hexane–EtOAc 1:1); mp 165–166 °C; [α]25D –164.7 (c 0.98, 
EtOH); IR (neat, cm−1): 3265 (OH), 1731 (C=O); 1H NMR (500 
MHz, CD3OD) δ 2.45 (s, 3H), 3.34 (d, J = 14.3 Hz, 1H), 3.41 (d, 
J = 16.6 Hz, 1H), 3.46 (d, J = 16.6 Hz, 1H), 3.67 (s, 3H), 4.34 (d, 
J = 14.3 Hz, 1H), 4.56 (dd, J = 10.9, 9.2 Hz, 1H), 5.04 (dd, J = 
9.2, 8.0 Hz, 1H), 5.26 (dd, J = 10.9, 8.0 Hz, 1H), 6.03 (s, 1H), 
6.63 (d, J = 7.4 Hz, 1H), 6.68 (d, J = 7.4 Hz, 1H), 7.07 (dd, J = 
7.4, 7.4 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 42.1, 51.9, 
56.2, 57.3, 58.2, 71.1, 115.8, 116.0, 118.1, 119.1, 130.2, 133.3, 
134.8, 154.4, 156.9, 173.0. Anal. calcd. for C16H18N2O5: C, 
60.28; H, 5.85; N, 8.72. Found C, 60.37; H, 5.70; N, 8.80. 
4.2 Formal synthesis of (–)-quinocarcinamide 
Synthesis of ethyl (R)-2-{[(10-methoxy-3-oxo-3,10b-dihydro-1H-
oxazolo[4,3-a]isoquinolin-5-yl)methyl](methyl)amino}acetate 
(15) (Scheme 3). Cs2CO3 (1.03 g, 3.16 mmol) was added to a 
stirred solution of 10 (0.33 g, 1.05 mmol) in acetone (50 mL) 
under argon at room temperature. After stirring the mixture for 
30 min, Me2SO4 (0.1 mL, 1.07 mmol) was added at –10 °C, and 
the resulting mixture was stirred for 4 h at 0 °C. H2O (50 mL) 
and EtOAc (50 mL) were added and the mixture was allowed to 
warm to room temperature. The organic phase was separated and 
washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. Purification by column chromatography over 
silica gel with n-hexane–EtOAc (2:1) gave the corresponding 
methyl ether as a yellow oil (0.34 g, 97%). 
K2CO3 (40.5 mg, 0.29 mmol) was added to a stirred solution 
of this methyl ether (19.5 mg, 0.06 mmol) in EtOH (2 mL) under 




















































































saturated aqueous NH4Cl (2 mL) was added. The resulting 
mixture was extracted with EtOAc. The extract was washed with 
H2O and brine, dried over MgSO4, and concentrated under 
reduced pressure followed by purification by column 
chromatography over silica gel with n-hexane–EtOAc (2:1) to 
give 15 as a yellow oil (12.9 mg, 63%): Rf = 0.47 (n-hexane–
EtOAc 1:1); [α]26D –199.8 (c 0.87, CHCl3); IR (neat, cm−1): 1761 
(C=O); 1H NMR (500 MHz, CDCl3) δ 1.27 (t, J = 7.2 Hz, 3H), 
2.51 (s, 3H), 3.42 (d, J = 16.6 Hz, 1H), 3.52 (d, J = 16.6 Hz, 1H), 
3.58 (d, J = 14.9 Hz, 1H), 3.81 (s, 3H), 4.17 (q, J = 7.2 Hz, 2H), 
4.30 (d, J = 14.9 Hz, 1H), 4.50 (dd, J = 10.9, 9.2 Hz, 1H), 4.98 
(dd, J = 9.2, 8.0 Hz, 1H), 5.27 (dd, J = 10.9, 8.0 Hz, 1H), 6.02 (s, 
1H), 6.73 (d, J = 8.0 Hz, 1H), 6.76 (d, J = 8.6 Hz, 1H), 7.22 (dd, 
J = 8.6, 8.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 14.3, 41.6, 
54.7, 55.4, 56.1, 57.6, 60.3, 69.4, 109.7, 112.7, 118.2, 119.1, 
129.3, 132.4, 135.3, 154.6, 155.0, 171.2; HRMS (FAB) calcd for 
C18H23N2O5 (MH+): 347.1607; found: 347.1609. 
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